Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. RNK Health's programs involve compounded prescription medications that require evaluation by a licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Consult your healthcare provider before beginning any weight management program.
What Is RNK Health?
RNK Health (myrnk.com) is a telehealth-based weight management and longevity platform that connects patients with licensed physicians who evaluate eligibility for compounded GLP-1 medications — primarily compounded semaglutide and compounded tirzepatide — along with wellness therapies including NAD+ and Sermorelin. The model mirrors the growing category of online-first GLP-1 clinics: patients complete a digital health assessment, a licensed physician reviews the information and determines eligibility, and if a prescription is appropriate, medication is compounded at a licensed U.S. pharmacy and shipped directly to the patient's door.
What distinguishes RNK Health from many competitors in this space is the inclusion of a dedicated personal coach at no additional cost with every plan. In a market where coaching is often a premium add-on—or absent entirely—this bundled structure is worth honest examination, which this review does. We cover the program structure, verified pricing, medication options, pharmacy transparency, and the key questions any informed patient should ask before starting.
For a broader overview of what compounded GLP-1 medications are and how they differ from FDA-approved brand-name options, see our educational primer on RNK Health and compounded GLP-1 therapy.
What Medications Does RNK Health Offer?
RNK Health's primary treatment offerings involve the two most-studied GLP-1 active pharmaceutical ingredients in the weight management category: semaglutide and tirzepatide. Both are available only through a licensed provider evaluation, not over the counter.
Compounded semaglutide (injectable): Semaglutide is a GLP-1 receptor agonist — meaning it binds to the same receptor as the body's naturally occurring glucagon-like peptide-1 hormone, which plays a role in appetite signaling, gastric emptying rate, and insulin regulation. The FDA-approved injectable forms of semaglutide for chronic weight management are Wegovy (2.4 mg weekly) and Ozempic (approved for type 2 diabetes, sometimes prescribed off-label for weight management at a clinician's discretion). RNK Health's compounded semaglutide contains the same active pharmaceutical ingredient but is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer — an important distinction covered in detail below.
Compounded semaglutide (oral dissolving): RNK Health also offers an oral semaglutide format. Oral administration of semaglutide raises pharmacokinetic considerations worth understanding. The FDA-approved oral semaglutide tablet (Rybelsus) uses a specialized absorption enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC) to achieve meaningful bioavailability. Most compounded oral semaglutide formulations — including oral dissolving tablets and lozenges — do not use this technology, and independent pharmacokinetic data on their absorption characteristics is limited. Patients considering oral compounded semaglutide should discuss expected bioavailability with their provider.
Compounded tirzepatide (injectable): Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Where semaglutide targets one receptor, tirzepatide targets two. In the SURMOUNT-1 randomized controlled trial — a peer-reviewed study published in the New England Journal of Medicine — participants without diabetes taking tirzepatide at 15 mg weekly lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% in the placebo group. FDA-approved tirzepatide for weight management is marketed as Zepbound (15 mg maximum weekly dose) and for diabetes as Mounjaro. RNK Health's compounded tirzepatide contains the same active ingredient in compounded form.
NAD+ and Sermorelin: RNK Health also offers NAD+ (nicotinamide adenine dinucleotide) supplementation starting at $129/month in injectable, nasal spray, and liposomal formats, as well as Sermorelin, a growth hormone releasing hormone analog. These fall outside the GLP-1 category and are not the primary focus of this review. Patients interested in these programs should discuss the evidence base and their individual suitability with a licensed provider.
Verified Pricing (as of Publication)
Pricing transparency is a legitimate differentiator in the GLP-1 telehealth space, where hidden fees and membership tiers are common. Based on publicly available information reviewed by our editorial team, RNK Health's published pricing structure is as follows:
Injectable semaglutide: $197/month, all-inclusive. Oral semaglutide: $198/month, all-inclusive. Injectable tirzepatide: $297/month, all-inclusive. All plans include medication, licensed physician consultation and prescription management, personal coaching, required supplies (syringes, alcohol swabs), and shipping. RNK Health states there are no hidden fees and the model is month-to-month with no long-term contract or cancellation penalty.
For context: brand-name Wegovy has a list price above $1,300/month, and brand-name Zepbound starts near $1,086/month at list price. Compounded alternatives from established competitors typically run $197–$399/month for semaglutide and $249–$399/month for tirzepatide, often without coaching included. RNK Health's tirzepatide pricing at $297/month all-inclusive is competitive for a plan that includes active physician oversight and personal coaching. Always verify current pricing directly with RNK Health before enrollment, as telehealth pricing in this category changes frequently.
The Coaching Model: What It Includes and What to Ask
Bundled personal coaching is the element RNK Health emphasizes most prominently. For patients new to GLP-1 therapy, this matters: GLP-1 medications reduce appetite, but long-term outcomes depend substantially on what patients do with that reduced appetite in terms of protein intake, resistance exercise, and behavioral anchoring. A personal coach who communicates with the prescribing physician and monitors progress can, in principle, help prevent common failure modes like muscle loss from inadequate protein intake during a caloric deficit.
What we cannot independently verify: the specific credentials or qualifications of RNK Health's coaches, the frequency and format of coaching touchpoints, or whether coaching interactions are primarily automated, asynchronous messaging, or synchronous calls. These are specific questions patients should ask during or before the intake process. A coaching program that consists of weekly check-in messages is substantively different from one that includes regular video or phone calls with a credentialed dietitian or health coach — and both can be marketed as “personal coaching.”
Pharmacy Transparency: What to Confirm Before Starting
RNK Health's compounding pharmacy is located at 863 W 450 S, Suite 101, Springville, UT 84663. The prescribing medical provider address is listed as 317 Sixth Avenue, Des Moines, Iowa 50309. This level of pharmacy address disclosure is better than many competitors in this space, who provide no pharmacy identification at all.
What patients should confirm directly: whether the pharmacy holds 503A or 503B designation with their state board, whether it appears on the FDA's list of registered outsourcing facilities, and whether it tests finished product for potency and sterility. These questions are reasonable, answerable, and the mark of a transparent compounding operation. A pharmacy that cannot answer them clearly is a pharmacy worth avoiding.
RNK Health states medications ship within 48 hours of physician approval via private home delivery. The program is available across all 50 states.
What the Clinical Evidence Shows About These Medications
It is important to distinguish between the evidence base for the active pharmaceutical ingredients (semaglutide and tirzepatide) and the evidence base for RNK Health as a specific program. The former is substantial. The latter involves no independent peer-reviewed outcomes data — which is true of virtually every telehealth GLP-1 platform, not a specific criticism of RNK Health.
For semaglutide: the STEP-1 randomized controlled trial (Wilding et al., New England Journal of Medicine, 2021) found that adults with obesity without diabetes who received semaglutide 2.4 mg weekly combined with lifestyle intervention lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo plus lifestyle group. For tirzepatide: the SURMOUNT-1 randomized controlled trial (Jastreboff et al., New England Journal of Medicine, 2022) found average weight loss of 15.0%, 19.5%, and 20.9% at tirzepatide doses of 5, 10, and 15 mg respectively over 72 weeks, compared with 3.1% in the placebo group. These trials used brand-name, FDA-approved formulations — not compounded versions. Individual results from compounded products may differ, and no compounded-specific outcome trials have been published as of this writing.
For broader context on how compounded semaglutide compares to tirzepatide specifically within RNK Health's program structure, see our semaglutide vs. tirzepatide decision guide for RNK Health patients.
Who RNK Health May Be Appropriate For
Based on standard GLP-1 prescribing criteria, candidates for GLP-1 receptor agonist therapy typically include adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Prescribing decisions rest entirely with the licensed physician who reviews your intake form and health history — not with the platform itself, and not with this article.
RNK Health may not be appropriate for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, current or planned pregnancy, a history of pancreatitis, end-stage kidney or liver disease, or certain other contraindications. Patients should disclose their complete medical history during the intake process. For a complete overview of risk factors and side effects, see our dedicated RNK Health side effects and safety guide.
Our Assessment
RNK Health is a structurally transparent GLP-1 telehealth program in a market that rewards opacity. All-inclusive pricing, a disclosed pharmacy address, 50-state availability, month-to-month flexibility, and bundled coaching at no additional cost are genuine differentiators — not marketing language that dissolves under scrutiny. The oral semaglutide bioavailability question and the coaching credential question are legitimate gaps that informed patients should close before enrolling. Neither is a disqualifying concern; both are questions with answerable answers.
What RNK Health is: a legitimate telehealth pathway to physician-supervised compounded GLP-1 therapy with competitive all-inclusive pricing and an above-average support model for this category. What it is not: a substitute for a comprehensive metabolic evaluation, ongoing lab monitoring, or a relationship with a primary care provider who knows your full health picture. These programs work best when they complement existing medical care — not when they replace it.
To see how RNK Health stacks up directly against other leading GLP-1 telehealth platforms on pricing, coaching, pharmacy transparency, and access to brand-name medications, see our full RNK Health vs. competitors comparison.
Frequently Asked Questions
What medications does RNK Health offer?
RNK Health offers compounded semaglutide in injectable and oral formats, compounded tirzepatide in injectable form, NAD+ therapy, and Sermorelin. All prescription medications require licensed physician evaluation before a prescription is issued.
How much does RNK Health cost?
As of publication, RNK Health's pricing starts at $197/month for injectable semaglutide, $198/month for oral semaglutide, and $297/month for tirzepatide. All plans include medication, physician oversight, personal coaching, supplies, and shipping. Verify current pricing directly with RNK Health.
Is RNK Health available in all states?
RNK Health states it operates in all 50 states. Patients should confirm availability in their specific state during the intake process.
Are RNK Health's medications FDA-approved?
No. RNK Health's GLP-1 medications are compounded. Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products and have not undergone FDA review for safety, effectiveness, or quality. They contain FDA-approved active pharmaceutical ingredients but are prepared by a compounding pharmacy rather than a pharmaceutical manufacturer.
Does RNK Health include coaching?
Yes. RNK Health includes a dedicated personal coach with every plan at no additional cost. Patients should ask about coach credentials, touchpoint frequency, and the format of coaching interactions before enrolling.